Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Penwest Pharmaceuticals has signed a development and licensing agreement with Cobalt Laboratories to develop a formulation of an undisclosed compound utilizing Penwest's TIMERx drug delivery technology.
Subscribe to our email newsletter
Under the terms of the agreement, Penwest will receive undisclosed fees and payments.
Jennifer Good, president and CEO of Penwest, said: “These arrangements fit with our strategy of leveraging the value of our proprietary drug delivery technologies to provide additional financial benefit to Penwest while permitting us to focus our internal resources on building our own product pipeline.”